<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043704</url>
  </required_header>
  <id_info>
    <org_study_id>13072</org_study_id>
    <nct_id>NCT02043704</nct_id>
  </id_info>
  <brief_title>RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain</brief_title>
  <official_title>The Effect of Intravenous Acetaminophen on Post-operative Pain and Narcotic Consumption in Vaginal Reconstructive Surgery Patients: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial will evaluate the effects of perioperative intravenous (IV)
      acetaminophen on postoperative narcotic consumption and pain scores in subjects undergoing
      vaginal reconstructive surgery. One hundred subjects will be randomly assigned to receive
      either IV acetaminophen or IV placebo. Those in the IV acetaminophen group will receive
      1000mg IV every 6 hours for 24 hours beginning prior to anesthesia induction. The control
      group will receive placebo saline infusions at the same time intervals. All subjects will
      receive as needed (prn) IV narcotic for additional pain relief. Visual analog scales (VAS)
      regarding pain will be evaluated at 18 and 24 hours postoperative and immediately prior to
      discharge. We will also collect total IV narcotic consumption. We hypothesize that subjects
      receiving IV acetaminophen will have lower VAS scores and decreased total narcotic
      consumption in comparison to the control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see brief summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain While Active - 18 hr</measure>
    <time_frame>18 hours</time_frame>
    <description>Post operative pain will be assessed 18 hours after surgery. Pain will be self reported by patients using a 0-100 mm visual analog scale (VAS) with 0 indicating no pain and 100 indicating the worst pain imaginable. A pain score will be collected for pain while active.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of Narcotic Consumption in the First 24 Hours Post Surgery</measure>
    <time_frame>24 hours</time_frame>
    <description>Hydromorphone will be administered for breakthrough pain. The total amount consumed in the first 24 hours post surgery will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Narcotic Associated Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>The incidence of known narcotic associated side effects will be recorded for nausea/vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Rescue Narcotic</measure>
    <time_frame>24 hours</time_frame>
    <description>The time from the end of surgery to the time any IV narcotic is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic Associated Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>The incidence of known narcotic associated side effects will be recorded for itching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic Associated Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>The incidence of known narcotic associated side effects will be recorded for headache.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic Associated Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>The incidence of known narcotic associated side effects will be recorded for insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic Associated Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>The incidence of known narcotic associated side effects will be recorded for rash/hives.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic Associated Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>The incidence of known narcotic associated side effects will be recorded for shortness of breath.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic Associated Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>The incidence of known narcotic associated side effects will be recorded for respiratory depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic Associated Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>The incidence of known narcotic associated side effects will be recorded for urinary retention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulation</measure>
    <time_frame>1800 minutes</time_frame>
    <description>Length of time from the end of surgery to the time of ambulation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to First Flatus/Bowel Movement</measure>
    <time_frame>9000 minutes</time_frame>
    <description>Length of time from the end of surgery to the time of first flatus or bowel movement.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen</intervention_name>
    <description>Details covered in arm description.</description>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Ofirmev</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between the ages of 18 and 70 years

          -  Patients of the Division of Urogynecology at Good Samaritan and Bethesda North
             Hospitals in Cincinnati, Ohio

          -  Scheduled to undergo major vaginal reconstruction

          -  Must undergo total vaginal hysterectomy, anterior repair, posterior repair, enterocele
             repair, and intraperitoneal vault suspension. The addition of suburethral sling is not
             a cause for exclusion.

        Exclusion Criteria:

          -  Allergy to acetaminophen

          -  Liver disease (chronic or active)

          -  Chronic alcohol use (&gt;1 drink/day)

          -  Bleeding diathesis

          -  Renal disease

          -  Opiate dependent or daily use

          -  History of chronic pain

          -  Mental or cognitive disorder preventing patient to accurately verbalize pain levels

          -  Undergoing abdominal or laparoscopic procedures at the time of surgery

          -  Allergy to hydromorphone

          -  Surgery is not performed under general anesthesia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catrina Crisp, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>TriHealth Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TriHealth - Good Samaritan and Bethesda North Hospitals</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <results_first_submitted>October 11, 2017</results_first_submitted>
  <results_first_submitted_qc>February 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 14, 2018</results_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IV Acetaminophen</keyword>
  <keyword>Vaginal Reconstruction</keyword>
  <keyword>Pain, Postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IV Acetaminophen</title>
          <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IV Acetaminophen</title>
          <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="12.8"/>
                    <measurement group_id="B2" value="59.4" spread="11.4"/>
                    <measurement group_id="B3" value="58.3" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain While Active - 18 hr</title>
        <description>Post operative pain will be assessed 18 hours after surgery. Pain will be self reported by patients using a 0-100 mm visual analog scale (VAS) with 0 indicating no pain and 100 indicating the worst pain imaginable. A pain score will be collected for pain while active.</description>
        <time_frame>18 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain While Active - 18 hr</title>
          <description>Post operative pain will be assessed 18 hours after surgery. Pain will be self reported by patients using a 0-100 mm visual analog scale (VAS) with 0 indicating no pain and 100 indicating the worst pain imaginable. A pain score will be collected for pain while active.</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" lower_limit="27.5" upper_limit="61"/>
                    <measurement group_id="O2" value="50.0" lower_limit="28.5" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The comparison was analyzed using the Mann-Whitney U test.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference in the pain scores between the groups.</non_inferiority_desc>
            <p_value>0.328</p_value>
            <p_value_desc>The p-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>There were no adjustments.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Narcotic Consumption in the First 24 Hours Post Surgery</title>
        <description>Hydromorphone will be administered for breakthrough pain. The total amount consumed in the first 24 hours post surgery will be recorded.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Narcotic Consumption in the First 24 Hours Post Surgery</title>
          <description>Hydromorphone will be administered for breakthrough pain. The total amount consumed in the first 24 hours post surgery will be recorded.</description>
          <units>mgs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="6.67" upper_limit="26.68"/>
                    <measurement group_id="O2" value="15" lower_limit="5" upper_limit="26.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Associated Side Effects</title>
        <description>The incidence of known narcotic associated side effects will be recorded for nausea/vomiting.</description>
        <time_frame>24 hours</time_frame>
        <population>Count reported for nausea/vomiting.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Associated Side Effects</title>
          <description>The incidence of known narcotic associated side effects will be recorded for nausea/vomiting.</description>
          <population>Count reported for nausea/vomiting.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Rescue Narcotic</title>
        <description>The time from the end of surgery to the time any IV narcotic is given.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Rescue Narcotic</title>
          <description>The time from the end of surgery to the time any IV narcotic is given.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="18" upper_limit="64"/>
                    <measurement group_id="O2" value="41" lower_limit="22" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Associated Side Effects</title>
        <description>The incidence of known narcotic associated side effects will be recorded for itching.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Associated Side Effects</title>
          <description>The incidence of known narcotic associated side effects will be recorded for itching.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Associated Side Effects</title>
        <description>The incidence of known narcotic associated side effects will be recorded for headache.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Associated Side Effects</title>
          <description>The incidence of known narcotic associated side effects will be recorded for headache.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Associated Side Effects</title>
        <description>The incidence of known narcotic associated side effects will be recorded for insomnia.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Associated Side Effects</title>
          <description>The incidence of known narcotic associated side effects will be recorded for insomnia.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Associated Side Effects</title>
        <description>The incidence of known narcotic associated side effects will be recorded for rash/hives.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Associated Side Effects</title>
          <description>The incidence of known narcotic associated side effects will be recorded for rash/hives.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Associated Side Effects</title>
        <description>The incidence of known narcotic associated side effects will be recorded for shortness of breath.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Associated Side Effects</title>
          <description>The incidence of known narcotic associated side effects will be recorded for shortness of breath.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Associated Side Effects</title>
        <description>The incidence of known narcotic associated side effects will be recorded for respiratory depression.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Associated Side Effects</title>
          <description>The incidence of known narcotic associated side effects will be recorded for respiratory depression.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Associated Side Effects</title>
        <description>The incidence of known narcotic associated side effects will be recorded for urinary retention.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Associated Side Effects</title>
          <description>The incidence of known narcotic associated side effects will be recorded for urinary retention.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ambulation</title>
        <description>Length of time from the end of surgery to the time of ambulation.</description>
        <time_frame>1800 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ambulation</title>
          <description>Length of time from the end of surgery to the time of ambulation.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1295" lower_limit="1108" upper_limit="1462"/>
                    <measurement group_id="O2" value="1252" lower_limit="778" upper_limit="1459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to First Flatus/Bowel Movement</title>
        <description>Length of time from the end of surgery to the time of first flatus or bowel movement.</description>
        <time_frame>9000 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Flatus/Bowel Movement</title>
          <description>Length of time from the end of surgery to the time of first flatus or bowel movement.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3977" lower_limit="1437" upper_limit="5564"/>
                    <measurement group_id="O2" value="1899" lower_limit="1275" upper_limit="4580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IV Acetaminophen</title>
          <description>Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
IV Acetaminophen: Details covered in arm description.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Specialist</name_or_title>
      <organization>TriHealth</organization>
      <phone>513-862-2341</phone>
      <email>ganga_devaiah@trihealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

